2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 291-292
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Emerging Technologies, Gene Editing, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Genetic Disorders, Immunology, Neutropenia, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

748 KLF2-PYDC3 axis regulates neutrophil inflammasome activation and immunothrombosis in antiphospholipid antibody syndrome

Asha Thomas, PhD, Devashis Mukherjee, MD, MS2, Sriram Satyavolu3, Sarah Cioffi4, Katherine Wen5, Ernest Ricky Chan, PhD6, Lalitha Nayak, MD7
1 Indiana University School of Medicine, Indianapolis, Indiana, United States
2 Case Western Reserve University, Cleveland, Ohio, United States
3 Ohio State University, Columbus, United States
4 Case Western Reserve University, Cleveland, Ohio, United States
5 Case Western Reserve University, Cleveland, Ohio, United States
6 Case Western Reserve University, Cleveland, Ohio, United States
7 Indiana University School of Medicine, Indianapolis, Indiana, United States

Background: Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disorder characterized by pathogenic antiphospholipid antibodies (aPLAs) that promote recurrent arterial and venous thrombosis. Neutrophils are key mediators of APS-associated thrombosis through neutrophil extracellular trap (NET) formation and inflammasome activation. We previously demonstrated that aPLAs activate neutrophils and that neutrophils from aPLA-positive patients and mice treated with aPLAs exhibit reduced expression of the anti-inflammatory and anti-thrombotic transcription factor Krüppel-like factor 2 (KLF2). Although KLF2 maintains myeloid quiescence by suppressing inflammatory gene expression, its role in regulating neutrophil inflammasome activation remains unknown. Here, we identify a previously unrecognized KLF2–PYDC3 signaling axis that restrains neutrophil NLRP3 inflammasome activation and thromboinflammation. 

Objective: To determine whether KLF2 regulates neutrophil NLRP3 inflammasome activation and identify downstream mediators linking KLF2 deficiency to immunothrombosis in APS. 

Methods: Bone marrow neutrophils and macrophages were isolated from myeloid-specific KLF2-deficient (K2KO) mice and Cre littermate controls. Canonical NLRP3 inflammasome signaling was induced by lipopolysaccharide (LPS) priming followed by nigericin activation. Inflammasome activation was assessed by caspase-1 cleavage and extracellular IL-1β and IL-18 release. RNA sequencing identified KLF2-regulated genes, and co-immunoprecipitation assessed PYDC3 interactions with ASC and NLRP3. Arterial thrombosis was evaluated in established murine thrombosis models following administration of the β2-glycoprotein I/anti-β2-glycoprotein I immune complex (ApoH). Statistical analyses used unpaired two-tailed Student's t tests, with  P<0.05 considered statistically significant.

Results: KLF2-deficient neutrophils exhibited significantly enhanced canonical NLRP3 inflammasome activation following LPS/nigericin stimulation, as demonstrated by increased caspase-1 cleavage and elevated IL-1β and IL-18 secretion compared with Cre control neutrophils (P<0.01). This phenotype was neutrophil-specific and was not observed in macrophages. ApoH further potentiated inflammasome activation in KLF2-deficient neutrophils, whereas pharmacological inhibition of NLRP3 with MCC950 significantly mitigated inflammasome activation. RNA sequencing identified Pydc3, encoding the pyrin domain-only protein PYDC3, as one of the most significantly downregulated transcripts in KLF2-deficient neutrophils (fold change >2; adjusted P<0.001). Co-immunoprecipitation studies demonstrated that PYDC3 constitutively associates with ASC under basal conditions. Upon NLRP3 inflammasome activation, this interaction was diminished, permitting ASC association with NLRP3 and inflammasome assembly. Consistent with this mechanism, reduced PYDC3 expression in KLF2-deficient neutrophils was associated with increased ASC speck formation and enhanced IL-1β release, supporting PYDC3 as an endogenous inhibitor of ASC-dependent inflammasome assembly. Adoptive transfer of KLF2-deficient neutrophils in Cre mice demonstrated accelerated carotid artery thrombosis compared with Cre mice receiving Cre control neutrophils, and this prothrombotic phenotype was significantly attenuated by MCC950 treatment. Similarly, ApoH administration accelerated carotid artery thrombosis compared with vehicle-treated controls and ongoing studies are testing the benefit of MCC950 in this setting.

Conclusion: KLF2 is a critical transcriptional regulator of neutrophil inflammasome activation through maintenance of PYDC3 expression. Loss of KLF2, as shown in APS patients and mice with aPLA treatment, relieves PYDC3-mediated restraint of ASC-dependent inflammasome assembly, resulting in enhanced IL-1β production and immunothrombosis. These findings identify a previously unrecognized KLF2–PYDC3–NLRP3 regulatory axis linking neutrophil dysfunction to APS pathogenesis and nominate this pathway as a potential therapeutic target to selectively attenuate inflammation-driven thrombosis while preserving hemostasis. Ongoing studies are exploring how ApoH exposure results in decreased KLF2 expression and laters PYDC3 homologs in humans.

 

Lalitha Nayak, MD: No relevant conflicts of interest to declare.